» Articles » PMID: 1563791

Gamma Interferon Mediates Propionibacterium Acnes-induced Hypersensitivity to Lipopolysaccharide in Mice

Overview
Journal Infect Immun
Date 1992 May 1
PMID 1563791
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Pretreatment of lipopolysaccharide (LPS)-responder C57BL/10ScSn mice with killed Propionibacterium acnes enhanced tumor necrosis factor alpha (TNF-alpha) production and lethality in response to a subsequent challenge with LPS. Sensitization to LPS increased with time of pretreatment and reached its maximum after 7 days. Sensitization was paralleled by gamma interferon (IFN-gamma) production that was detectable from day 3 onward. In contrast, a similar P. acnes pretreatment of LPS-nonresponder C57BL/10ScCr mice had no apparent effect on their high resistance to LPS. Challenge with LPS at any time during the 7-day period after P. acnes treatment led to no detectable TNF-alpha formation and caused no lethal effects. The absence of sensitization in C57BL/10ScCr mice was paralleled by an absence of IFN-gamma production. Administration of monoclonal IFN-gamma antibodies in C57BL/10ScSn mice up to day 3 of P. acnes treatment completely inhibited the overproduction of TNF-alpha by LPS. Anti-IFN-gamma administered later than day 3 had only a partial, although significant, inhibitory effect. Injection of appropriate amounts of anti-IFN-gamma also abolished the development of hypersensitivity to the lethal action of LPS. The effect of exogenously administered IFN-gamma on LPS sensitivity (e.g., TNF-alpha production, lethal effects) was studied in LPS-responder and nonresponder mice. Administration of murine recombinant IFN-gamma increased the sensitivity of C57BL/10ScSn mice to LPS and established LPS responsiveness in LPS-nonresponder C57BL/10ScCr and C3H/HeJ mice. The data provide evidence that IFN-gamma mediates the sensitization towards LPS induced by P. acnes.

Citing Articles

Autoinflammatory bone disorders: update on immunologic abnormalities and clues about possible triggers.

Sharma M, Ferguson P Curr Opin Rheumatol. 2013; 25(5):658-64.

PMID: 23917160 PMC: 4912130. DOI: 10.1097/BOR.0b013e328363eb08.


TLR9-dependent and independent pathways drive activation of the immune system by Propionibacterium acnes.

Tchaptchet S, Gumenscheimer M, Kalis C, Freudenberg N, Holscher C, Kirschning C PLoS One. 2012; 7(6):e39155.

PMID: 22745710 PMC: 3382180. DOI: 10.1371/journal.pone.0039155.


Macrophage activation by lipopolysaccharide, interferon-gamma and interleukin-4: effect of fatty acid metabolism.

Darmani H, Harwood J, Parton J, Jackson S Mediators Inflamm. 1995; 4(1):25-30.

PMID: 18475612 PMC: 2365606. DOI: 10.1155/S0962935195000056.


Carnitine and congeners as regulators of tumour necrosis factor.

De Simone C, Martelli E, Foresta P Mediators Inflamm. 1993; 2(7):S3.

PMID: 18475567 PMC: 2365450. DOI: 10.1155/S0962935193000663.


Bacterial endotoxins: biological properties and mechanisms of action.

Galanos C, Freudenberg M Mediators Inflamm. 1993; 2(7):S11-6.

PMID: 18475562 PMC: 2365449. DOI: 10.1155/S0962935193000687.


References
1.
Kagaya K, Watanabe K, Fukazawa Y . Capacity of recombinant gamma interferon to activate macrophages for Salmonella-killing activity. Infect Immun. 1989; 57(2):609-15. PMC: 313140. DOI: 10.1128/iai.57.2.609-615.1989. View

2.
OGarra A . Interleukins and the immune system 2. Lancet. 1989; 1(8645):1003-5. DOI: 10.1016/s0140-6736(89)92640-8. View

3.
Blanchard D, Djeu J, Klein T, Friedman H, Stewart 2nd W . Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. J Immunol. 1986; 136(3):963-70. View

4.
Beutler B, Tkacenko V, Milsark I, Krochin N, Cerami A . Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype. J Exp Med. 1986; 164(5):1791-6. PMC: 2188450. DOI: 10.1084/jem.164.5.1791. View

5.
Gifford G, Lohmann-Matthes M . Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J Natl Cancer Inst. 1987; 78(1):121-4. DOI: 10.1093/jnci/78.1.121. View